Key Highlights
- Amylyx Pharmaceuticals' Phase 3 LUCIDITY trial for avexitide achieved its primary FDA-agreed endpoint in post-bariatric hypoglycemia.
- The GLP-1 receptor antagonist delivered a 55% reduction in Level 2/3 hypoglycemic events compared to placebo.
- The study also met all secondary goals.
- The results pave the way for a year-end 2026 NDA filing for what could be the first approved PBH treatment.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that its Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia achieved its primary FDA-agreed endpoint, with the GLP-1 receptor antagonist delivering a 55% reduction in Level 2/3 hypoglycemic events compared to placebo.
What Happened
The study also met all secondary goals, paving the way for a year-end 2026 NDA filing for what could become the first approved treatment for post-bariatric hypoglycemia.
Market Reaction
The disclosed information does not include stock price or trading data for Amylyx Pharmaceuticals following the trial results.
Outlook
The planned year-end 2026 NDA filing represents the next major disclosed milestone for avexitide, which would position the company to potentially deliver the first approved treatment specifically for post-bariatric hypoglycemia.
FAQs
Q: Did Amylyx Pharmaceuticals' Phase 3 LUCIDITY trial meet its primary endpoint?
A: Yes, avexitide achieved its primary FDA-agreed endpoint, with a 55% reduction in Level 2/3 hypoglycemic events compared to placebo.
Q: What condition is avexitide being developed to treat?
A: Post-bariatric hypoglycemia (PBH).
Q: What is the next regulatory step for avexitide?
A: A planned NDA filing by year-end 2026, which could make it the first approved PBH treatment.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.